Single‑session high‑dose lung radiotherapy and its effects on outcomes and quality of life

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational multicenter study follows adults receiving single‑fraction stereotactic body radiotherapy (30–34 Gy) for peripheral lung tumors ≤3 cm that are inoperable or for patients with up to three lung metastases. Participants are enrolled at Montpellier and Lorraine cancer centers and undergo routine clinical follow‑up with imaging and standardized quality‑of‑life questionnaires. The study records local control, toxicity, survival outcomes, and patient‑reported quality of life to characterize real‑world effects of monofraction SBRT. Collected data aim to inform how single‑session treatment integrates into routine practice compared with multi‑fraction approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age: ≥ 18 years
* Patient receiving single-fraction stereotactic body radiation therapy (SBRT)
* Stage T1-2 N0 M0 non-small cell lung cancer (NSCLC) (AJCC 6th edition) or oligometastatic lung tumor defined by ≤ 3 lung metastasis.
* Inoperability: Tumor is inoperable or patient refuses surgery
* Tumor size: ≤ 3 cm
* Peripheral tumors: \> 2 cm from proximal bronchial tree but ≥ 0.5 cm from the wall
* Histologically proven or with evolution criteria (CT scan and PET scan)
* ECOG performance status: 0-2
* Ability to comply: Willingness and ability to comply with scheduled visits and other study procedures
* Informed consent: Written informed consent obtained
* Insurance: Patient is affiliated with a French health insurance plan

Exclusion Criteria:

* Tumors invading the pleura or mediastinum.
* Concurrent infectious pneumonia or pericarditis.
* Prior radiotherapy to the treatment field.
* Presence of neoadjuvant treatment for the present cancer.
* Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
* Patients under guardianship, curatorship or safeguard of justice,
* Pregnant or breast-feeding subjects
* Concomitant participation or participation within the last 30 days in another clinical trial
* Patient with an estimated life expectancy of less than 6 months.

Where it's running

• Montpellier Cancer Institut
  Montpellier, Icm, France Recruiting
• Lorraine Cancer Institute
  Vandœuvre-lès-Nancy, France Not yet recruiting

Study contacts

• Study coordinator: Aurore Moussion
• Email: DRCI-soumissions@icm.unicancer.fr
• Phone: 0467613102

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating KQB365 for treating advanced solid tumors

  This study tests if a new treatment called KQB365, alone or with another drug, can help adults with advanced solid tumors that have specific genetic mutations.

  Recruiting at 11 sites Phase 1 Kumquat Biosciences Inc. · Phoenix, Arizona and 10 other locations · NCT06720987

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

• Icotinib after surgery for early EGFR-mutant NSCLC

  This study tests whether giving icotinib after surgery helps patients with early-stage EGFR-mutant NSCLC compare to just following them after surgery.

  Recruiting at 2 sites Betta Pharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07806604

• Pelvic ultra-hypofractionated radiotherapy after surgery for high-risk endometrial cancer

  This trial tests whether giving 27.5 Gy in five sessions of pelvic radiotherapy after surgery is safe and feasible for high-risk endometrial cancer patients.

  Recruiting Instituto de Investigación Sanitaria Aragón · Zaragoza, Zaragoza · NCT07779109

• Oral Paclitaxel with Immunotherapy and SBRT as Neoadjuvant Treatment for Older Adults with NSCLC

  This trial tests a new, lighter neoadjuvant therapy that combines an oral paclitaxel solution, an immune checkpoint inhibitor, and SBRT for adults aged 70 and older with resectable NSCLC to see if it can shrink tumors before surgery.

  Recruiting Phase 4 Shanghai Pulmonary Hospital, Shanghai, China · Guangzhou, Guangdong and 4 other locations · NCT07754812

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.